Authored By: B. V Waghmare

Tuesday, May 31, 2011

New nonnucleoside reverse transcriptase inhibitors for treating patients who never recived any anti retroviral drug before

New drug is now available for HIV positive patients who have never taken any treatment.

There is a new drug development in the treatment of HIV positive individual, now a new drug is approved by US food and drugs administration , the new drug is a non nucleoside reverse transcriptase inhibitor, which can be used to lower the higher HIV 1 viral load in blood of HIV positive individuals which never received any anti retroviral treatment before, as the task is a challenging one the newly available drug will be able to provide better tratement option in such cases along with HAART.

Brand name of this drug is Edurant which contains rilpivirine, Raritan, N.J-based Tibotec Therapeutics, a division of Centocor Ortho Biotech Inc has developed this drug.

Rilpivirine
The drug molecule rilpivirine is a diarylpyrimidine derivative which resembles the pyrymidine nucleotides in complementroy DNA and tymine nucleotide in RNA in HIV virus  which, owing to its similarity to the chemical resemblance to pryamidine nucleotides, It act by inhibiting HIV virus replication, by blocking enzyme reverse transcriptase. Rilpivirine drug molecule also exhibit some level of conformational isomerism which make this drug molecule to bind with pryrimidine nucleosides strongly preventing them from replication, making this drug molecule active even in higher HIV viral load conditions.

Nucleotide reverse transcriptase inhibitor drugs have therapeutic index to a lower side (moderate) compared to non nucleoside reverse transcriptase inhibitors, that means they nonnucleoside reverse transcriptase inhibitors posses less toxic side effects than nucleotide reverse transcriptase inhibitor drugs , although there is greater likely hood of developing drug resistance in case of nonnucleocide reverse transcriptase inhibitors, the drug should not be discontinued once it is started and a desired low viral level is maintained throughout. There are also some drug resistance assays available with which one can predict the likely hood of drug resistance with a particular antiretroviral drug.

Edurant rilpivirine is approved by US food and drugs administration as a drug to be used in a highly active antiretroviral therapy (HAART) regimen which is targeted to reduce the HIV virus load in the infected individual . The dose of the drug is once a day pill taken with food.

The drug can be used in patients who had not received any prior HIV therapy as the drug Edurant (rilpivirine) in a clinical trail effectively reduced the initial higher HIV viral load in the blood of infected individuals to a level of HIV virus undetectable level is blood.

Side effects include (insomnia) difficulty sleeping, headache,depression, and rash.
The drug Edurant(rilpivirine) do not cure HIV or AIDS ( no drug in the world cure HIV AIDS rather they help in improving quality of life and extending life) therefore US FDA has advised patients to stay on with continuous with their therapy for HIV and related diseases. and other AIDS symptoms

Source:
http://aac.asm.org/cgi/content/full/48/10/3684?view=long&pmid=15388420

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256087.htm




=================================================================
Links for more information over treatment for HIV positive and AIDS symptoms , new drug research and development on HIV vaccine research, latest updates.



No comments: